KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Travere Therapeutics (TVTX) EPS (Weighted Average and Diluted) (2016 - 2025)

Travere Therapeutics (TVTX) has disclosed EPS (Weighted Average and Diluted) for 13 consecutive years, with -$0.25 as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, EPS (Weighted Average and Diluted) rose 64.79% year-over-year to -$0.25, compared with a TTM value of -$0.57 through Dec 2025, up 86.03%, and an annual FY2025 reading of -$0.57, up 86.03% over the prior year.
  • EPS (Weighted Average and Diluted) was -$0.25 for Q4 2025 at Travere Therapeutics, down from $0.29 in the prior quarter.
  • Across five years, EPS (Weighted Average and Diluted) topped out at $0.29 in Q3 2025 and bottomed at -$1.86 in Q4 2022.
  • Average EPS (Weighted Average and Diluted) over 5 years is -$0.88, with a median of -$0.93 recorded in 2024.
  • The sharpest move saw EPS (Weighted Average and Diluted) tumbled 4900.0% in 2021, then surged 140.85% in 2025.
  • Year by year, EPS (Weighted Average and Diluted) stood at -$0.84 in 2021, then tumbled by 121.43% to -$1.86 in 2022, then skyrocketed by 37.63% to -$1.16 in 2023, then surged by 38.79% to -$0.71 in 2024, then soared by 64.79% to -$0.25 in 2025.
  • Business Quant data shows EPS (Weighted Average and Diluted) for TVTX at -$0.25 in Q4 2025, $0.29 in Q3 2025, and -$0.14 in Q2 2025.